Treat Endocrinol. 2006;5(4):257-63. doi: 10.2165/00024677-200605040-00007.
New treatments and treatment protocols for endocrine disorders are evolving rapidly, and research and development activity in the endocrinology field is high. Optimal therapy remains contentious in some areas. To help you keep up to date with the latest advances worldwide on all aspects of drug therapy and management of endocrine disorders, this section of the journal brings you information selected from the rapid drug news alerting service Inpharma WeeklyInpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details. The use of trade names, identified by ['~'] or the use of a registered (((R))) or trademark (trade mark) symbol, is for product identification purposes only and does not imply endorsement.. Each issue contains easy-to-read summaries of the most important research and development news, clinical studies, treatment guidelines, pharmacoeconomic and adverse drug reaction news, and expert opinion pieces published in the world's top endocrinology journals.
内分泌疾病的新治疗方法和治疗方案正在迅速发展,内分泌学领域的研发活动十分活跃。在某些领域,最佳治疗方案仍存在争议。为帮助您及时了解全球范围内内分泌疾病药物治疗和管理各方面的最新进展,本刊的这一部分为您带来从快速药物新闻警报服务《Inpharma Weekly》中精选的信息。《Inpharma Weekly》提供有关药物和药物治疗的新闻快速警报。该时事通讯由阿迪斯国际有限公司制作,通过汇总从1600多种生物医学期刊中选取的信息,以多种格式提供。如需订阅详情,请联系您最近的阿迪斯办公室。使用由['~']标识的商品名或注册的(((R)))或商标符号仅用于产品识别目的,并不意味着认可。每期都包含世界顶级内分泌学期刊上发表的最重要研发新闻、临床研究、治疗指南、药物经济学和药物不良反应新闻以及专家意见文章的易读摘要。